mRNA Vaccine and Immune Modulator Combination Patent Application

ChangeBridge: Patent Apps - Biotech (C12N)

Detected March 27th, 2026

Summary

The USPTO has published a patent application (US20260083837A1) for a combination comprising mRNA molecules for vaccines or therapeutic proteins, along with immune-modulating mRNA. The application details combinations for improved or reduced immunogenicity to increase efficacy, and relates to host cells, pharmaceutical compositions, vaccines, and kits for medical use.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260083837A1, detailing a combination therapy involving mRNA molecules. The invention focuses on a combination of at least one mRNA molecule encoding a therapeutic or immunogenic protein/peptide and at least one second mRNA molecule that modulates the immune response to the first molecule or its translation product. This aims to improve or reduce immunogenicity, thereby increasing efficacy. The application also covers host cells, pharmaceutical compositions, vaccines, kits, and their use in preventing or treating infectious, genetic, or proliferative diseases.

This patent application signifies a new development in mRNA technology and its therapeutic applications. While it does not impose immediate compliance obligations, it is highly relevant for pharmaceutical and biotechnology companies involved in mRNA research and development. Companies should monitor the progress of this patent application, as granted patents can impact intellectual property landscapes, licensing opportunities, and competitive strategies in the vaccine and therapeutic protein markets. Understanding the scope of the claims will be crucial for R&D planning and freedom-to-operate analyses.

Source document (simplified)

← USPTO Patent Applications

COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY

Application US20260083837A1 Kind: A1 Mar 26, 2026

Inventors

Emanuele SASSO, Alfredo NICOSIA

Abstract

The present invention pertains to a combination comprising two or more mRNA molecules, or a single mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and/or the translation product of the first molecule, wherein the combination comprises at least one first mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and at least one second mRNA molecule encoding a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and/or the translation product of the first molecule. The invention also relates to a host cell comprising a combination or the single mRNA molecule according to the present invention, a pharmaceutical composition comprising the combination, the single mRNA molecule, or the host cell of the present invention, and a vaccine comprising the combination, the single mRNA molecule, the host cell, or the pharmaceutical composition according to the present invention. Further provided is a kit comprising the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, or the vaccine according to the present invention. The invention also pertains to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in medicine. Finally, the invention also relates to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in a method of prevention, and/or treatment of an infectious, a genetic, or a proliferative disease.